Corient Private Wealth LLC Has $31.54 Million Stake in CVS Health Corporation $CVS

Corient Private Wealth LLC boosted its position in shares of CVS Health Corporation (NYSE:CVS) by 6.1% during the 4th quarter, HoldingsChannel reports. The firm owned 397,228 shares of the pharmacy operator’s stock after buying an additional 22,764 shares during the quarter. Corient Private Wealth LLC’s holdings in CVS Health were worth $31,540,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Caitong International Asset Management Co. Ltd grew its holdings in shares of CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 281 shares in the last quarter. Swiss RE Ltd. purchased a new stake in CVS Health in the 4th quarter worth about $26,000. Sankala Group LLC acquired a new stake in CVS Health during the 4th quarter worth about $28,000. Mcguire Capital Advisors Inc. purchased a new position in CVS Health during the 4th quarter valued at about $28,000. Finally, Ares Financial Consulting LLC acquired a new position in shares of CVS Health in the 4th quarter valued at about $29,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Price Performance

NYSE CVS opened at $98.26 on Monday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $125.38 billion, a PE ratio of 43.29, a price-to-earnings-growth ratio of 0.96 and a beta of 0.62. CVS Health Corporation has a 12-month low of $58.50 and a 12-month high of $102.77. The company has a 50 day moving average price of $89.31 and a two-hundred day moving average price of $81.50.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. CVS Health’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Wall Street Zen raised shares of CVS Health from a “hold” rating to a “buy” rating in a research report on Sunday. Wolfe Research lowered their price objective on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. DA Davidson upped their price objective on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Morgan Stanley lifted their target price on shares of CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a research note on Thursday, June 4th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $113.00 price target on shares of CVS Health in a research note on Monday, June 1st. Twenty-two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $100.68.

Insider Activity

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the sale, the director directly owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. 0.85% of the stock is currently owned by corporate insiders.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.